FDA Deramiocel Duchenne Approval Blocked After HOPE-3 Data Findings

November 22, 2026
4 mins read
Cross-section of gastrocnemius muscle from a Duchenne muscular dystrophy patient, with muscle fibers replaced by adipose cells.
A cross-section of gastrocnemius muscle from a Duchenne muscular dystrophy patient shows muscle fibers replaced by fat cells. The FDA's Nov. 20, 2026 complete response letter leaves Capricor's deramiocel unapproved until new controlled trial evidence is available (photo: CDC Public Health Image Library, public domain).
FDA Issues Complete Response Letter for Capricor’s Deramiocel BLA for Duchenne Muscular Dystrophy For families affected by Duchenne muscular dystrophy, the FDA’s deramiocel decision means the evidence in Capricor Therapeutics’ application did not meet the standard for approval in the United States. On November 20, 2026, the agency issued a Complete Response Letter and a Regulatory Responsibility Letter following its review of the application and a Bioresearch Monitoring inspection. The FDA said Study HOPE-3 failed to meet its prespecified primary and secondary efficacy endpoints. Its inspection also identified serious data integrity problems, including unauthorized post hoc changes to the statistical analysis plan, violations of blinding procedures, and additional protocol violations. The agency said the deficiencies could not be remedied after the fact. CBER’s Office of Therapeutic Products issued the Complete Response Letter. The FDA also issued a Regulatory Responsibility Letter dated November 20 concerning observations from its inspection. A Complete Response Letter means the application was not approved as submitted. Capricor will have the opportunity to address the issues in the Regulatory Responsibility Letter. Deramiocel is an allogeneic cardiosphere-derived cell therapy developed for people with Duchenne muscular dystrophy, a genetic disease that causes progressive muscle weakness. The application’s proposed use changed during the FDA review. Capricor initially sought treatment for cardiomyopathy associated with DMD, then proposed upper limb impairment after a July 29, 2026, advisory committee meeting. The company also submitted 24-month open-label extension data from Study HOPE-3-OLE as a major amendment to its application. The FDA said it considered the additional data and the changed proposed indication, but the evidence still did not meet the standard for approval. For patients and families, the decision means deramiocel has not received U.S. approval on the evidence reviewed. The FDA did not specify what additional evidence or steps would be needed for a future application, or when or whether Capricor will submit one.

Why the FDA issued a Complete Response Letter

The FDA said Study HOPE-3 did not meet its prespecified primary and secondary efficacy endpoints. These are the outcomes a trial sets in advance to measure whether a treatment works. Capricor has reported that the trial met its primary endpoint; the FDA’s assessment was that it did not, citing its analysis of the prespecified endpoints. The FDA also cited unauthorized post hoc changes to the statistical analysis plan—the document that specifies how researchers will evaluate results—violations of study blinding, and additional protocol violations. Blinding is intended to prevent expectations from influencing trial conduct or assessment. The agency said the violations, individually and collectively, compromised the reliability of the data, which it did not consider reliable or interpretable for establishing substantial evidence of effectiveness. The FDA said the deficiencies could not be remedied after the study ended. The distinction between the two letters matters: the Complete Response Letter communicated that the BLA was not approved as submitted; the Regulatory Responsibility Letter addressed observations from the Bioresearch Monitoring inspection. Together, the FDA’s statement and letters indicate that the extension data and revised proposed use did not change the agency’s conclusion that the evidence was insufficient. The FDA said flexibility in rare-disease reviews cannot come at the cost of reliable data. Its Rare Disease Framework Initiative, launched in October 2026, is intended to develop a tailored regulatory framework for rare diseases. Patients considering research options can also read about a pancreatic cancer trial’s survival findings in our daraxonrasib trial report. A separate Class II guidewire recall article explains how FDA safety actions can address different kinds of medical risks. The FDA did not specify the next step or what further evidence would be required. Its statement does not give a resubmission date or describe a specific new study plan. It also does not say that the HOPE-3-OLE data can substitute for reliable evidence of effectiveness from the main study. For families and clinicians, deramiocel has not received U.S. approval on the evidence reviewed. Any future submission would need to satisfy the FDA’s approval standard and address the concerns identified in the letters. The agency’s statement also references its Rare Disease Framework Initiative, while leaving the timing and path of any further Capricor submission unstated.

Tejal Somvanshi

Meet Tejal Somvanshi, a soulful wanderer and a staunch wellness advocate, who elegantly navigates through the enchanting domains of Fashion and Beauty with a natural panache. Her journey, vividly painted with hues from a vibrant past in the media production world, empowers her to carve out stories that slice through the cacophony, where brands morph into characters and marketing gimmicks evolve into intriguing plot twists. To Tejal, travel is not merely an activity; it unfolds as a chapter brimming with adventures and serendipitous tales, while health is not just a regimen but a steadfast companion in her everyday epic. In the realms of fashion and beauty, she discovers her muse, weaving a narrative where each style narrates a story, and every beauty trend sparks a dialogue. Tejal seamlessly melds the spontaneous spirit of the media industry with the eloquent prose of a storyteller, crafting tales as vibrant and dynamic as the industry she thrives in.

Leave a Reply

Your email address will not be published.

A Great Lakes freighter sails beneath a vertical-lift bridge at a harbour entrance, with a lighthouse on the pier.
Previous Story

Sault Ste. Marie Port Secures $250M for Great Lakes Marine Terminal

Latest from Health

Don't Miss

Two flexible endoscopes hang from a wall-mounted storage rack, with their control heads at the top and insertion tubes hanging down.

FDA Classifies Diversatek SafeGuide Guidewire Recall Class 2

The Diversatek SafeGuide guidewire recall covers two models